The THCA Therapeutics corporate website has entered a new stage of development following the completion of the latest investor, business, intellectual-property, formulation-control and product-series documents.

The website content is being updated to reflect the current strategic and scientific position of the project, including:

The rheumatoid-arthritis lead program.

The revised THCA PURE™ Oral cap-in-softgel formulation.

The milestone-gated development strategy.

The updated intellectual-property and validation approach.

The current $6 million Seed-financing objective.

The distinction between published evidence, company hypotheses, planned studies and future development goals.

The updated website will provide a clearer communication platform for investors, researchers, pharmaceutical-development partners, advisors and other stakeholders evaluating THCA Therapeutics.

Public product language will continue to identify THCA PURE™ Oral as investigational and not approved. The website will not present the formulation as clinically validated, proven safe, effective, stable, bioavailable, proprietary or patent protected unless those conclusions are supported by future evidence, regulatory status or completed intellectual-property actions.

This update connects the public digital presence of THCA Therapeutics with the company’s latest controlled documentation and evidence standards.